1 r donors (47 of which were randomized and 53
nonrandomized).
2 10), single-group pretest/posttest (n = 2),
nonrandomized 2-group (n = 13), and randomized clinical
3 One hundred forty
nonrandomized,
6 randomized open-label, and 2 randomized
4 (ADAPT-DES) was a prospective, multicenter,
nonrandomized "
all-comers" study of 8583 consecutive pat
5 ty score analysis was used to adjust for the
nonrandomized allocation of treatments.
6 In
nonrandomized analyses, faster weight gain in infancy wa
7 In a post hoc,
nonrandomized analysis from the FREEDOM (Future REvascul
8 Retrospective
nonrandomized analysis is subject to residual confoundin
9 This large comprehensive
nonrandomized analysis of longitudinal HRQL shows that T
10 We performed a
nonrandomized analysis of survival/cardiovascular events
11 This is a post hoc,
nonrandomized analysis of the completeness of revascular
12 patient data were used for a retrospective,
nonrandomized analysis.
13 The selection was
nonrandomized and nonprospectively collected.
14 There have been decades of
nonrandomized and observational data available, but only
15 These data are
nonrandomized and thus preliminary, providing the founda
16 Initial,
nonrandomized and uncontrolled studies show success rate
17 However, although they are
nonrandomized and were not placebo-controlled, the prese
18 ed 22 controlled trials (8 randomized and 14
nonrandomized)
and 17 pre/post or time series studies.
19 ratified by the type of study (randomized vs
nonrandomized)
and were significant only in randomized t
20 Inclusion criteria were all randomized,
nonrandomized,
and retrospective studies with data on SC
21 f SNP was chosen by the attending clinician,
nonrandomized,
and titrated to a target mean arterial pr
22 In
nonrandomized as-treated comparisons with careful contro
23 LECTION: Intervention studies (randomized or
nonrandomized)
assessing the efficacy of earplugs as a s
24 Patients were assigned in a
nonrandomized but specified manner to receive treatment
25 This is a prospective, interventional,
nonrandomized case series of patients undergoing office-
26 This was a
nonrandomized chart review of eyes with subluxated intra
27 ntial consideration was given to prospective
nonrandomized clinical and preclinical studies.
28 Several
nonrandomized clinical studies have recently addressed t
29 Nonrandomized clinical study with historical controls.
30 Multicenter, retrospective,
nonrandomized clinical study.
31 Inotrope Dependent) trial was a prospective,
nonrandomized clinical trial comparing LVAD with optimal
32 A
nonrandomized clinical trial evaluating the LINKAGE inte
33 f lentiviral vectors in a phase I open-label
nonrandomized clinical trial for HIV.
34 nical observer-blinded study (6 patients), 4
nonrandomized clinical trials (133 patients), 1 cohort s
35 Eight randomized and 9
nonrandomized clinical trials compared treatments with o
36 Nonrandomized clinical trials with definitive end points
37 ooled from 655 enrolled patients (135 from a
nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ip
38 Using a
nonrandomized cohort of 742,909 non-emergent, isolated C
39 A large,
nonrandomized cohort of chlamydia screening among US Arm
40 This was an observational,
nonrandomized cohort study evaluating cell-mediated and
41 In this observational,
nonrandomized cohort study, the 5-year DRFS for treated
42 Prospective
nonrandomized cohort study.
43 ty of all surgically treated patients in the
nonrandomized cohort was 30% (95% CI: 26%-35%) and 26% (
44 week of LT) were included in a retrospective
nonrandomized cohort.
45 In each of these countries,
nonrandomized comparative clinical trials were initiated
46 We conducted a retrospective,
nonrandomized comparative effectiveness study of dose-es
47 ature search identified randomized (RCT) and
nonrandomized comparative observational clinical studies
48 Selection of high-quality,
nonrandomized comparative studies (NRCTs) was based on a
49 Randomized and
nonrandomized comparative studies that enrolled children
50 Seventeen randomized controlled trials and 3
nonrandomized comparative studies were included in this
51 nalyses, 26 randomized controlled trials, 11
nonrandomized comparative studies, 20 cohort studies, an
52 were randomized controlled trials, six were
nonrandomized comparative studies, and 14 were single-ar
53 HCC and waiting for LT, there were only two
nonrandomized comparative studies, both with a high risk
54 Retrospective,
nonrandomized,
comparative clinical study.
55 An observational,
nonrandomized,
comparative multicenter cohort study was
56 ction: Randomized, controlled trials (RCTs);
nonrandomized,
comparative studies (NRCSs); single-group
57 ials (RCTs) and prospective or retrospective
nonrandomized,
comparative studies of medical therapy al
58 In this
nonrandomized,
comparative study, 99 patients of various
59 Retrospective,
nonrandomized,
comparative study.
60 reatment but were retained in the study as a
nonrandomized comparison group.
61 In a single-center, prospective,
nonrandomized comparison study, BRCA mutation carriers a
62 In a
nonrandomized comparison within our trial center, we fou
63 bias cannot be ruled out, because this is a
nonrandomized comparison.
64 Nonrandomized comparisons are liable to provide misleadi
65 However,
nonrandomized comparisons of self-reported outcomes are
66 ppears similar to open-radical cystectomy in
nonrandomized comparisons.
67 Retrospective,
nonrandomized,
consecutive case series.
68 SETTING, AND PARTICIPANTS: A retrospective,
nonrandomized,
consecutive cohort study of a total of 20
69 A
nonrandomized,
consecutive design was used for glycemic
70 the randomized controlled trial (n=574) and
nonrandomized continued access (n=1358) cohorts were div
71 5 patients undergoing TA-TAVR in the PARTNER
nonrandomized continued access (NRCA) registry and compa
72 nd mortality in these 2 arms and in the TAVR
nonrandomized continued access (NRCA) registry cohort.
73 In the
nonrandomized continued access cohort, there were no dif
74 randomized controlled trial cohort A and the
nonrandomized continued access cohort.
75 of Aortic Transcatheter Valve) trial and the
nonrandomized continued access registry.
76 Data comparing the two techniques are
nonrandomized,
contradictory, and utilize historical con
77 Small,
nonrandomized controlled studies suggested benefit from
78 aintenance, a randomized controlled trial, a
nonrandomized controlled trial, and an observational lon
79 ndomized controlled trials (n = 2554) and 11
nonrandomized controlled trials (n = 917) for inclusion
80 ception to May 2012 to locate randomized and
nonrandomized controlled trials of patients receiving ac
81 c review and meta-analysis of randomized and
nonrandomized controlled trials to determine whether wei
82 Nine randomized controlled trials and 13
nonrandomized controlled trials were selected from 216 r
83 y criteria: 1 randomized controlled trial, 4
nonrandomized controlled trials, 3 quasi-experimental tr
84 tations, including five randomized and seven
nonrandomized controlled trials.
85 e Subjects study is an ongoing, prospective,
nonrandomized,
controlled intervention study conducted i
86 In a prospective, 3-center,
nonrandomized,
controlled study, 2 sequential groups of
87 Nonrandomized crossover trial involving 6 healthy adults
88 , we illustrate challenges involved in using
nonrandomized data for this purpose with a case study fr
89 Nonrandomized data sources may inform the initial design
90 This
nonrandomized data suggests no advantage for 4 mg over t
91 The largest body of randomized and
nonrandomized data to date has been for the Watchman dev
92 These
nonrandomized data were consistent with previous trials
93 em to be achievable, based on the results of
nonrandomized data.
94 0th century because of conflicting and often
nonrandomized data.
95 To reduce bias by residual confounding in
nonrandomized database studies, the high-dimensional pro
96 The study was a retrospective,
nonrandomized design that assessed a limited number of o
97 Using a retrospective,
nonrandomized design with propensity score matching, the
98 Using a
nonrandomized design, we compared rates of injuries from
99 Rather than viewing randomized and
nonrandomized designs as in competition, they should be
100 elines, including prospective randomized and
nonrandomized double-blind, single-blind, and open-label
101 We conducted
nonrandomized effectiveness studies of ADT plus RT versu
102 The study sought a prospective multicenter
nonrandomized evaluation of the Direct Flow Medical (DFM
103 MET and VEGFR2, was evaluated in a phase II
nonrandomized expansion study in castration-resistant pr
104 ence showing the conditions under which some
nonrandomized experiments may be able to approximate res
105 another, short interrupted time series, and
nonrandomized experiments using a nonequivalent comparis
106 oth randomized and-perhaps more surprisingly-
nonrandomized experiments.
107 including a propensity score, to adjust for
nonrandomized ICD implantation after (123)I-mIBG.
108 Thirty-seven studies (32 randomized and 5
nonrandomized)
including 4326 patients met inclusion cri
109 In the observational study, 74
nonrandomized individuals were followed up prospectively
110 were observed between the randomized and the
nonrandomized intervention groups.
111 ords to identify randomized clinical trials,
nonrandomized intervention studies, and observational st
112 This prospective
nonrandomized interventional cohort analysis performed a
113 A prospective
nonrandomized interventional cohort study was conducted.
114 Prospective, crossover,
nonrandomized interventional study.
115 Retrospective,
nonrandomized,
interventional case series.
116 We performed a prospective, multicenter,
nonrandomized investigation evaluating the safety and ef
117 rmed a prospective, multicenter, controlled,
nonrandomized investigation of self-expanding TAVR in pa
118 with a retrospective review of consecutive,
nonrandomized,
longitudinal case series of KPro implanta
119 gastroplasty (69%), or gastric bypass (12%);
nonrandomized,
matched, prospective controls received us
120 End-of-preschool follow-up of a
nonrandomized,
matched-group cohort of predominantly low
121 lity weighted (IPW) hazard ratios (HRs) in a
nonrandomized Medicare-linked (age >/=65 years) patient
122 ized crossover, 1 randomized parallel, and 3
nonrandomized)
met the inclusion criteria.
123 in the prospective, multicenter, open-label,
nonrandomized ML-DS 2006 trial by Nordic Society for Ped
124 This prospective
nonrandomized multicenter study was approved by the revi
125 In a prospective,
nonrandomized multicenter trial, 45 eligible patients re
126 vascularized were enrolled in a prospective,
nonrandomized,
multicenter investigation testing percuta
127 This prospective,
nonrandomized,
multicenter trial included adult patients
128 ge recommendation, a phase I-II, open-label,
nonrandomized,
multicenter trial was therefore designed
129 enotyping were enrolled in this prospective,
nonrandomized,
multicenter, phase II study of IPI-504 mo
130 This prospective,
nonrandomized,
national quality improvement program meas
131 should be interpreted cautiously, given the
nonrandomized nature and the selection bias of the study
132 Because of the
nonrandomized nature of this study, the indications for
133 Because of the
nonrandomized nature of this study, these results should
134 2 clinical trial with a parallel, untreated,
nonrandomized observational cohort of CSF biomarker-nega
135 llel, randomized clinical trial, including a
nonrandomized observational group, conducted at 2 public
136 In real-world
nonrandomized observational studies with greater numbers
137 Our
nonrandomized,
observational data suggest that implement
138 ETHOD: This 5-year, prospective, open-label,
nonrandomized,
observational registry study was conducte
139 In this prospective,
nonrandomized,
observational study, the choice of proced
140 Prospective,
nonrandomized,
observational study.
141 d RV failure are rare and usually limited to
nonrandomized observations.
142 We conducted a
nonrandomized,
off-label, pilot, phase I/II study of ale
143 In this phase 2,
nonrandomized,
open-label clinical trial conducted at th
144 Nonrandomized,
open-label clinical trial initiated in 20
145 r 2 outcomes: (1) blood pressure changes for
nonrandomized,
open-label randomized, and blinded studie
146 In
nonrandomized,
open-label studies, a transcatheter inter
147 This phase 2,
nonrandomized,
open-label study evaluated brentuximab ve
148 We conducted a phase 3,
nonrandomized,
open-label study of the safety, efficacy,
149 We conducted a 24-month,
nonrandomized,
open-label trial to determine whether sir
150 We conducted a
nonrandomized,
open-label, multicenter, phase 4 study.
151 METHODS AND A prospective, multicenter,
nonrandomized,
open-label, single-arm study of carotid a
152 This
nonrandomized,
parallel group, pharmacokinetic evaluatio
153 In this
nonrandomized,
parallel-cohort, phase 1b, multicenter st
154 s the therapeutic benefit of SNB in a large,
nonrandomized patient cohort.
155 Of the
nonrandomized patients in the observational study group,
156 Nonrandomized patients were followed in a prospective co
157 The VITAL study was an open-label
nonrandomized phase 3 trial conducted to evaluate the ef
158 significantly from the 12-month score in the
nonrandomized phase among the 23 participants in the the
159 KEYNOTE-012 was a multicenter,
nonrandomized phase Ib trial of single-agent pembrolizum
160 ls, has shown promising clinical efficacy in
nonrandomized phase II trials in patients with ovarian c
161 d in a National Cancer Institute open-label,
nonrandomized,
phase 2 clinical trial.
162 atment and household RUTF use.We conducted a
nonrandomized pilot intervention study in which 115 chil
163 The results of this uncontrolled and
nonrandomized pilot study suggest that the safety of rit
164 In this
nonrandomized population of patients selected for surger
165 urope), a European prospective, multicenter,
nonrandomized post-approval study of MitraClip therapy (
166 hed cohort designs can estimate impacts from
nonrandomized,
preexisting interventions that are used w
167 gn to study the impact and sustainability of
nonrandomized,
preexisting interventions.
168 in vivo were administered in an open-label,
nonrandomized,
proof-of-concept study to attempt to prev
169 In this
nonrandomized prospective study, gray matter structure w
170 In a
nonrandomized prospective trial, 168 patients who were a
171 Participants were from an ongoing, matched (
nonrandomized)
prospective intervention trial of the Swe
172 e Subjects (SOS) study, which was a matched (
nonrandomized)
prospective trial that compared bariatric
173 This report describes an open-label,
nonrandomized,
prospective evaluation of the effects of
174 ups, both randomized, controlled studies and
nonrandomized,
prospective, controlled studies were incl
175 sh Obese Subjects (SOS) study is an ongoing,
nonrandomized,
prospective, controlled study conducted a
176 In an analysis of data from a
nonrandomized,
prospective, controlled study, we examine
177 Nonrandomized publications were reviewed for the purpose
178 One multicenter randomized trial and several
nonrandomized registries have successfully established C
179 Multicenter,
nonrandomized registry of 1661 patients at intermediate
180 We conducted a 3-year, open-label,
nonrandomized registry of 594 patients with polyarticula
181 (n=542 patients) and those from a subsequent
nonrandomized registry of patients undergoing Watchman i
182 appropriate, the physician should consider a
nonrandomized registry, or consensus-based guidelines.
183 ment consists largely of single institution,
nonrandomized reports, limiting the ability to formulate
184 hd-PS is a flexible analytical tool for
nonrandomized research across a range of study sizes and
185 A
nonrandomized retrospective review.
186 In a
nonrandomized,
retrospective study, intravenous (IV) cal
187 DESIGN, SETTING, AND PATIENTS:
Nonrandomized Second-Generation Antipsychotic Treatment
188 detailed analysis of clinical outcomes in a
nonrandomized setting is warranted.
189 ND PATIENTS: Multi-institutional, unblinded,
nonrandomized single group phase 2 clinical trial to ass
190 An additional
nonrandomized single-arm cohort of 30 patients with nona
191 f 23 patients assessable for efficacy in the
nonrandomized single-arm extension cohort also responded
192 Nonrandomized,
single-blinded study using an interrupted
193 c cardiomyopathy have been limited to small,
nonrandomized,
single-center studies.
194 A
nonrandomized,
single-center, sequential study enrolled
195 This Phase I, open-label,
nonrandomized,
single-sequence study assessed the effect
196 f the 1489 studies originally identified, 13
nonrandomized studies (0.9%) representing 25,950 patient
197 Meta-analysis of 11
nonrandomized studies (8858 patients) revealed that dela
198 nce between randomized controlled trials and
nonrandomized studies (a term that is preferable to "out
199 Nonrandomized studies (NRSs) involving use of propensity
200 r comparing randomized controlled trials and
nonrandomized studies (p = 0.25) and unchanged over time
201 n comparing randomized controlled trials and
nonrandomized studies (p = 0.71), but decreased (p = 0.0
202 The meta-analysis included 11
nonrandomized studies and 5850 patients (1157 MV-PCI and
203 Nonrandomized studies and open-label randomized trials r
204 This analysis of both randomized and
nonrandomized studies evaluating an antiangiogenic agent
205 Meta-analyses of
nonrandomized studies have failed to demonstrate any sig
206 One of the major advantages of
nonrandomized studies is that they can make use of exist
207 Even after adjustment,
nonrandomized studies may have large biases, so are not
208 outcomes have been reported in a few small,
nonrandomized studies of a new approach to the Norwood p
209 Initially, 157 randomized and
nonrandomized studies on therapies (systemic immunomodul
210 Randomized and
nonrandomized studies reporting an intervention for colo
211 inception to 31 May 2014 for randomized and
nonrandomized studies reporting seroconversions among un
212 Nonrandomized studies suggest that subvalvular repair is
213 Nonrandomized studies suggest that thoracic epidural ana
214 The available evidence from mainly
nonrandomized studies suggests that extended or continuo
215 This meta-analysis of
nonrandomized studies suggests that in patients with car
216 There is evidence from
nonrandomized studies that a proportion of ipilimumab-tr
217 not consider a growing body of evidence from
nonrandomized studies that provides insight into the eff
218 We identified 3 small randomized and 18
nonrandomized studies that reported 68 cases of endophth
219 other treatment options; no information from
nonrandomized studies was available.
220 For
nonrandomized studies we compared bleeding risk with oth
221 ion on health outcomes of adult outpatients;
nonrandomized studies were eligible for harms.
222 enty-two randomized controlled trials and 71
nonrandomized studies were included.
223 Four randomized controlled trials and 22
nonrandomized studies were included.
224 these, 137 were randomized studies, 67 were
nonrandomized studies with 2 or more groups, and 405 use
225 ysis (one randomized controlled trial; three
nonrandomized studies with exposure limited to nighttime
226 randomized, controlled trials [RCTs] and 65
nonrandomized studies) met the inclusion criteria.
227 n a validated tool (Methodological Index for
Nonrandomized Studies).
228 Twenty-one studies comprising 13 prospective
nonrandomized studies, 1 prospective randomized, and 7 r
229 patients in 10 retrospective or prospective
nonrandomized studies, 621 (34.4%) of whom were sedated.
230 In small,
nonrandomized studies, an entirely subcutaneous ICD cons
231 a VT protocol was used postrandomization; in
nonrandomized studies, baseline VT and PPlat.
232 From
nonrandomized studies, cinacalcet appears to be safe and
233 udies, 4 randomized controlled trials, and 6
nonrandomized studies, which compared outcomes in heart
234 n acute HIV infection is predominantly small
nonrandomized studies, which further limits interpretati
235 ers is critical for successful adjustment in
nonrandomized studies.
236 C) is unclear, with conflicting results from
nonrandomized studies.
237 lytic techniques can improve the accuracy of
nonrandomized studies.
238 for analysis, including 7 randomized and 16
nonrandomized studies.
239 016 was conducted to identify randomized and
nonrandomized studies.
240 67 randomized clinical trials (RCTs) and 11
nonrandomized studies.
241 of renal autonomic nerves has been proven in
nonrandomized studies.
242 study was a randomized controlled trial or a
nonrandomized study and performed or not at an Acute Res
243 In a
nonrandomized study at 13 centers in 11 countries, 187 p
244 This prospective
nonrandomized study compared HRQL and survival after tho
245 s and Methods This was a prospective phase I
nonrandomized study conducted between March 2013 and Oct
246 NG, AND PATIENTS: A prospective, controlled,
nonrandomized study conducted during a control period (J
247 Recent data from a
nonrandomized study demonstrate fewer postoperative comp
248 Nonrandomized study design and small sample of patients
249 Despite the small sample size and
nonrandomized study design, these data suggest that a st
250 tients eligible to enroll in this open-label
nonrandomized study either met on-treatment criteria for
251 In this prospective, controlled,
nonrandomized study involving 11 901 patients at 15 Mich
252 ure Patients) is a prospective, multicenter,
nonrandomized study of 200 advanced heart failure patien
253 In this
nonrandomized study of carefully selected patients under
254 We conducted a prospective,
nonrandomized study of kidney transplantation in HIV-inf
255 This was a prospective,
nonrandomized study of mature accesses that underwent ba
256 We performed a prospective,
nonrandomized study to assess the safety of MRI at a mag
257 A multicenter, prospective,
nonrandomized study was conducted of LAA closure with th
258 A prospective, multicenter,
nonrandomized study was conducted.
259 In a prospective
nonrandomized study, a completely self-contained, single
260 ent in short-term survival was noted in this
nonrandomized study, but the long-term outcome remains u
261 rly approval of a new drug based on a robust
nonrandomized study, buttressed by data from concurrent
262 this multicenter, international, two-cohort,
nonrandomized study, we enrolled patients with metastati
263 rcept plus MTX for 3 years in an open-label,
nonrandomized study.
264 could not be definitively determined in this
nonrandomized study.
265 Prospective,
nonrandomized study.
266 A prospective, interventional,
nonrandomized study.
267 mple concerns changes in hemoglobin A1c in a
nonrandomized study.
268 clopidogrel or ticagrelor in a prespecified,
nonrandomized subgroup analysis of the Platelet Inhibiti
269 In a
nonrandomized subset of 165 infants (n=77 erythropoietin
270 he MRKAd5 HIV-1 vaccine, these findings in a
nonrandomized subset of enrollees show an HLA-specific v
271 n 40 +/- 8.7) was enrolled in a prospective,
nonrandomized supplement study.
272 , including a propensity score to adjust for
nonrandomized treatment allocation.
273 core matching was used to minimize bias from
nonrandomized treatment assignment.
274 opensity score method was used to adjust for
nonrandomized treatment selection.
275 ents (18.6%) were not enrolled but underwent
nonrandomized treatment with the same DESs.
276 Participants who were prescribed any
nonrandomized treatment without first meeting either det
277 Secondary analysis that included
nonrandomized trial data.
278 , we performed a single-center, prospective,
nonrandomized trial involving 36 patients with hematolog
279 We undertook a prospective,
nonrandomized trial of kidney transplantation in HIV-inf
280 ) were treated with DES in this prospective,
nonrandomized trial.
281 ndomized controlled trials (837 patients), 7
nonrandomized trials (338 patients), and 41 noncontrolle
282 written about the epidemiological issues in
nonrandomized trials aiming to evaluate the superiority
283 arisons of different treatment options using
nonrandomized trials demonstrate improved outcomes with
284 his study together with other randomized and
nonrandomized trials establish a definitive role for tha
285 d trials for pulmonary infection and only in
nonrandomized trials for mortality.
286 Randomized and
nonrandomized trials of first-line, salvage, and palliat
287 Case reports, RCTs, and
nonrandomized trials of probiotic use in patients also r
288 lished studies in uveitis are case series or
nonrandomized trials, there remains a lack of level 1 ev
289 as 0%-9% in randomized trials and 17%-23% in
nonrandomized trials.
290 ts, randomized controlled trials (RCTs), and
nonrandomized trials.
291 (95% CI: 2.59, 7.12 nmol/L) was observed in
nonrandomized trials.
292 ere enrolled in a prospective single-center,
nonrandomized,
unblinded investigation (Timing Based on
293 er were more likely to be smaller and to use
nonrandomized,
unblinded trial designs and surrogate end
294 We enrolled 47 patients in this open-label,
nonrandomized,
uncontrolled phase 2 study.
295 Open-label,
nonrandomized,
uncontrolled phase 3 trial conducted at 3
296 We enrolled 12 patients in an open-label,
nonrandomized,
uncontrolled study of a single dose of ZF
297 In this open-label,
nonrandomized,
uncontrolled study, a high rate of SVR12
298 In this open-label,
nonrandomized,
uncontrolled study, patients with HIV who
299 LIMITATION: Because this study was
nonrandomized,
unobserved differences may still exist be
300 ensity-matched analysis was adjusted for the
nonrandomized use of the 2 strategies.